Understanding how STING affects T cell death and cancer immunity
Deciphering the Roles of STING-Mediated T cell Pyroptosis in Antitumor Immunity
This study is looking at how a protein called STING affects the immune system's ability to fight cancer, especially how it can help or hinder T cells, which are important for battling tumors, to find out why some cancer treatments don't work as well as they should and to discover new ways to improve those treatments.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cleveland Clinic Lerner Com-Cwru NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project ID | NIH-10854276 on NIH RePORTER |
What this research studies
This research investigates the role of the STING protein in the immune response against tumors, particularly focusing on how it can both activate and inhibit T cells, which are crucial for fighting cancer. By studying the mechanisms of STING-mediated cell death in T cells within the tumor microenvironment, the research aims to uncover why some cancer treatments fail. The approach involves analyzing how STING activation influences various immune cells and their interactions in the presence of tumors. This could lead to new strategies to enhance the effectiveness of cancer therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with cancers that are resistant to existing immunotherapies, particularly those involving T cell therapies.
Not a fit: Patients with non-cancerous conditions or those whose tumors are not influenced by STING-mediated pathways may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved cancer treatments by overcoming resistance to current therapies.
How similar studies have performed: Previous research has shown that targeting immune pathways like STING can enhance antitumor responses, indicating potential for success in this area.
Where this research is happening
Cleveland, United States
- Cleveland Clinic Lerner Com-Cwru — Cleveland, United States (Active)
Researchers
- Principal investigator: Wu, Jianjun — Cleveland Clinic Lerner Com-Cwru
- Study coordinator: Wu, Jianjun
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.